Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

91,258 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction to: Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States.
Zeidan AM, Pollyea DA, Borate U, Vasconcelos A, Potluri R, Rotter D, Kiendrebeogo Z, Gaugler L, Prebet T, Strocchia M, Bonifacio G, Chen C. Zeidan AM, et al. Among authors: chen c. Ann Hematol. 2023 Aug;102(8):2299. doi: 10.1007/s00277-023-05327-x. Ann Hematol. 2023. PMID: 37341779 Free PMC article. No abstract available.
Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States.
Zeidan AM, Pollyea DA, Borate U, Vasconcelos A, Potluri R, Rotter D, Kiendrebeogo Z, Gaugler L, Prebet T, Strocchia M, Bonifacio G, Chen C. Zeidan AM, et al. Among authors: chen c. Ann Hematol. 2023 Apr;102(4):749-754. doi: 10.1007/s00277-023-05109-5. Epub 2023 Feb 3. Ann Hematol. 2023. PMID: 36732419 Free PMC article.
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial.
Janjigian YY, Ajani JA, Moehler M, Shen L, Garrido M, Gallardo C, Wyrwicz L, Yamaguchi K, Cleary JM, Elimova E, Karamouzis M, Bruges R, Skoczylas T, Bragagnoli A, Liu T, Tehfe M, Zander T, Kowalyszyn R, Pazo-Cid R, Schenker M, Feeny K, Wang R, Lei M, Chen C, Nathani R, Shitara K. Janjigian YY, et al. Among authors: chen c. J Clin Oncol. 2024 Jun 10;42(17):2012-2020. doi: 10.1200/JCO.23.01601. Epub 2024 Feb 21. J Clin Oncol. 2024. PMID: 38382001 Free PMC article. Clinical Trial.
Treatment Effect Waning in Immuno-oncology Health Technology Assessments: A Review of Assumptions and Supporting Evidence with Proposals to Guide Modelling.
Taylor K, Latimer NR, Douglas T, Hatswell AJ, Ho S, Okorogheye G, Borril J, Chen C, Kim I, Bertwistle D. Taylor K, et al. Among authors: chen c. Pharmacoeconomics. 2024 Nov;42(11):1181-1196. doi: 10.1007/s40273-024-01423-6. Epub 2024 Aug 23. Pharmacoeconomics. 2024. PMID: 39177877 Free PMC article. Review.
Genome-wide association study of anterior uveitis.
Koskimäki F, Ahokas O, Kajanne R, Saviauk KR, Elnahas A, Reigo A, Reis K, Esko T, Palta P, Leinonen S, Kettunen J, Liinamaa J, Karjalainen MK, Saarela V; Estonian Biobank Research Team Consortium; FinnGen Consortium; Estonian Biobank Research Team Consortium authors. Koskimäki F, et al. Br J Ophthalmol. 2024 Dec 27:bjo-2024-326037. doi: 10.1136/bjo-2024-326037. Online ahead of print. Br J Ophthalmol. 2024. PMID: 39732499
91,258 results
You have reached the last available page of results. Please see the User Guide for more information.